»ó´Ü¿©¹é
±â»ç (Àüü 385°Ç)
[Conference Report] ÇÇ¿À±Û¸®Å¸Á¸, SGLT-2iÀÇ ÀÌ»óÀûÀÎ ÆÄÆ®³Ê Á¤¿¬ÁÖ ±âÀÚ 2024-04-26 15:13
[Conference Report] SGLT-2i/TZD º´¿ëÀ¸·Î Ç÷´ç¡¤Ã¼Áß¡¤Ç÷¾Ð¡¤HF¡¤CKD¡¤NAFLD °ø·« THE MOST 2024-04-11 14:05
[Sub Story] Àν¶¸°ºÐºñ´É¡¤Àν¶¸°ÀúÇ×¼º °³¼±±âÀüÀÌ Ã³¹æ½ÃÀå ¾çºÐ ÀÌ»óµ· ±âÀÚ 2024-03-15 17:04
[Journal Briefing] Ç÷´ç°­ÇÏÁ¦ º´¿ë, ½ÉÇ÷°ü¡¤½ÅÀå ÇýÅà ½Ã»ç Á¤¿¬ÁÖ ±âÀÚ 2024-03-15 15:44
[Interview] ¡°SGLT-2i Ȳ±Ý±â´Â TZD¿Í º´¿ëÀ¸·ÎºÎÅÍ¡± ÀÌ»óµ· ±âÀÚ 2024-03-15 15:30
¶óÀÎ
[Drug Review] ÄÉ·»µð¾ÆÁ¤ Çã°¡¡¤±Þ¿©·Î
2Çü´ç´¢º´ µ¿¹Ý ¸¸¼º½ÅÀ庴 Ä¡·á ¿ÏÀüü °¡µ¿
ÀÌ»óµ· ±âÀÚ 2024-03-13 14:56
[Interview] ¡°1Â÷ÀÇ·á ´Ü°è¼­ºÎÅÍ ´ç´¢º´¼º ½ÅÀåÁúȯ ½Ï ã¾Æ³» À߶ó³»ÀÚ¡± ÀÌ»óµ· ±âÀÚ 2024-03-13 14:15
[Sub Story] Çѱ¹ÀÎ ´ç´¢º´ º´Å»ý¸®´Â ºñºö¹äÇü ÀÌ»óµ· ±âÀÚ 2024-03-12 15:41
[Sub Story] ´ç´¢º´ ȯÀÚ Ç×°íÇ÷¾ÐÁ¦ º´¿ë 150/90mmHg ÀÌ»óºÎÅÍ ÀÌ»óµ· ±âÀÚ 2024-02-07 15:43
[Sub Story] Ä¡·á¸ñÇ¥ ¼³Á¤¿¡¼­ ÃÖÀûÀÇ ¾àÁ¦¼±ÅñîÁö ÀÌ»óµ· ±âÀÚ 2024-02-07 15:36
¶óÀÎ
[Sub Story] Ç÷´ç°­ÇÏÁ¦ ¼±ÅñâÁØ È¿°ú¡¤ºÎÀۿ롤MACE¡¤½ÉºÎÀü¡¤½ÅÀåÁúȯ ÀÌ»óµ· ±âÀÚ 2024-02-07 15:30
[RTM] 2024³â ´ç´¢º´ °ü¸®Àü·« ¾÷µ¥ÀÌÆ® THE MOST 2024-02-07 14:50
[Journal Briefing] AKD µ¿¹Ý 2Çü´ç´¢º´ ȯÀÚ¿¡¼­ SGLT-2i¿Í »ç¸ÁÀ§ÇèÀº ¿¬°üÀÖÀ»±î? Á¤¿¬ÁÖ ±âÀÚ 2024-02-07 14:23
[Journal Briefing] GLP-1RA ½ÉÇ÷°ü ÇýÅà SGLT-2i º´¿ë¿¡ ¿µÇâ¹ÞÁö ¾Ê¾Æ Á¤¿¬ÁÖ ±âÀÚ 2024-02-07 14:22
[Journal Briefing] ¾Æ½Ã¾Æ¿¡¼­µµ ´ÙÆı۸®Ç÷ÎÁø À¯È¿¼º ÀÏ°üµÅ Á¤¿¬ÁÖ ±âÀÚ 2024-02-07 13:53
¶óÀÎ
[Conference Report] SGLT-2i+TZD, Ç÷´çÁ¶Àý¿¡¼­ Ç¥ÀûÀå±â º¸È£È¿°ú±îÁö ½Ã³ÊÁö ±â´ë THE MOST 2024-02-07 13:19
[Cover Story] ¼öøÀ¸·Î º¸´Â 2024 ADA °¡À̵å¶óÀÎ ÀÌ»óµ· ±âÀÚ 2024-02-07 09:49
[Journal Briefing] Áöº¸ÅÙź º´¿ë¿ä¹ýÀ¸·Î ½ÅÀå º¸È£È¿°ú ³ô¿© Á¤¿¬ÁÖ ±âÀÚ 2024-01-11 16:33
[Cover Story] 2Çü´ç´¢º´ ¾à¹°Ä¡·á ¾Ë°í¸®µë µû¶óÀâ±â ÀÌ»óµ· ±âÀÚ 2023-11-08 13:31
[Sub Story] Ç÷´ç¡¤µ¿¹ÝÁúȯ ¹¯°í ´äº¯¿¡ ºÎÇÕÇÏ´Â ¾àÁ¦Ã³¹æ ÀÌ»óµ· ±âÀÚ 2023-11-08 12:04
Back to Top